HIGH DOSE ACYCLOVIR VS VIDARABINE IN RX OF NEONATAL HERPES SIMPLEX INFECTION

高剂量阿昔洛韦与阿糖腺苷治疗新生儿单纯疱疹感染的比较

• 批准号: 3738939
• 负责人: ROBERT F PASS
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3738939
• 关键词: Herpes simplex disease; acyclovir; drug administration rate /duration; human subject; human therapy evaluation; infectious encephalitis; microorganism disease chemotherapy; newborn human (0-6 weeks)

This collaborative study of neonatal herpes simplex virus infection will evaluate high dose acyclovir (60mg/kg/day) versus vidarabine (30mg/kg/day) for 21 days in the treatment of neonatal HSV infection in babies with encephalitis (CNS) or disseminated disease.

这项新生儿单纯疱疹病毒感染的合作研究将 评价高剂量阿昔洛韦（60 mg/kg/天）与阿糖腺苷 (30mg/kg/天）治疗新生儿HSV感染21天， 患有脑炎（CNS）或播散性疾病的婴儿。